# **Curriculum Vitae**

### **Pooneh Ghavidel Parsa**

- **First and surname:** Pooneh Ghavidel Parsa

- **Born in**: Rasht

- **Birth date:** 1971. 07.22

- **Email:** pooneh.gil@gmail.com

H index / Citations = 3/86 based on google scholar and 3/51based on Scopus at 30 October 2024.
Google scholar: <a href="https://scholar.google.com/citations?user=4DRnDYAAAAAJ&hl=en&oi=ao">https://scholar.google.com/citations?user=4DRnDYAAAAAJ&hl=en&oi=ao</a>

- **Scopus ID:** 57062941600

- **Orchid ID:** 0000-0002-7295-1548

#### Education

MD: School of medicine, Guilan university of medical sciences, Rasht, IR Iran (1990 - 1998)

### Scientific Memberships and Other Responsibilities

- Working in Gil clinic (private owner) in Rasht (From 2000 to 2024)
- Manager in Guilan rheumatology research center in Guilan university of medical sciences, Rasht, IR Iran (From 2011 to present)
- Member of research committee of guilan rheumatology research center (From 2011 to present)
- Member of committee of development of diseases registries in Guilan university of medical sciences, Rasht, IR Iran (From 2017 to 2019)
- Reviewer in clinical rheumatology journal (From 2017 to present)
- Member of Iran fibromyalgia disease registry (From 2018 to present)
- Collaboration in developing Iran dentistry guideline for elderly and disabled (2019)
- One of executives of Iran primary Sjogren syndrome registry (From 2019 to present)
- Iran primary Sjogren syndrome strategic and scientific committee (From 2019 to present)
- Member of Iran diabetes mellitus guideline (2021)
- Membership of Cochrane collaboration (From 2021 for 5 years )
- Supervisor of ethical committee of Guilan university of medical sciences for Perkinra multicenter RCT III (IR.TUMS.VCR.REC.1398.992) at 2020 2021
- Supervisor of ethical committee of Guilan university of medical sciences for denosumab in metastaic breast cancer treatment multicenter RCT III (IR.SBMU.CRC.REC.1399.025 ) at 2021 2023

### **Awards and Honors**

- Certificate of appreciation: Awarded in recognition for collaboration in adalimumab national multicenter RCT (2016)
- Exemplary physician award: Recognition as the exemplary physician at Guilan university of medical sciences (2017)
- Letter of Commendation: Awarded in recognition of valuable contributions and dedicated efforts in the launch of the university's new site, as well as foundational work to enhance the quality and configuration of the associated subportal in alignment with the university's strategic objectives (2022)
- Certificate of appreciation: Awarded in recognition as exemplary employee at Razi Educational, Research and Treatment Hospital of Guilan medical university (2023)
- Certificate of appreciation: Awarded in recognition of collaborative efforts in disease registry, contributing to the Guilan medical university achievement of the first place in research infrastructure metric (2024)

## **Curriculum Vitae**

### **Pooneh Ghavidel Parsa**

### **Skills**

- Diseases registry development
- Systematic review and meta-analysis
- Guideline development
- STATA, G power
- Learning Python, R, Designing a platform for Iran disease registries
- Visio
- Clinical pathway and Application development for primary Sjogren syndrome

#### **Publications**

- The factors affecting bone density in cirrhosis. 2015. (Citations in: scholar = 27, Scopus = 15)
- Secondary Sjogren's syndrome in 83 patients with rheumatoid arthritis. 2016. Correspond. (Citations in: scholar = 48, Scopus = 27)
- Pulmonary involvement in rheumatoid arthritis: A cross-sectional study in Iran. 2016. (Citations in: scholar = 13, Scopus = 8)
- The risk of systemic lupus erythematosus associated with human Herpesvirus 8 (HHV-8) infection: A systematic review and meta-analysis. 2021. (Citations in: scholar = 0, Scopus = 0)
- Iran diabetes mellitus guideline (2021: National Guideline in Persain)
- Dental caries among the elderly in Iran: a meta-analysis. 2024 (Citations in: scholar = 1, Scopus =1)
- An Early View of Iran Primary Sjogren Syndrome Registry (Guilan Province Pilot Phase), an Emerging Effort for a National Registry Establishment. 2024. Correspond. Accepted

### **Other Collaborations**

- Collaboration with pharmaceutical industries including:
  - 1. Aryogen in Denosumab national multicenter RCT (Phase III) and Altebrel post marketing survey (Phase IV)
  - 2. Cinnagen in Adalimumab national multicenter RCT (Phase III) and Cinnopar post marketing survey (Phase IV)
  - 3. OrchidPharmed in TocilliZumab national multicenter RCT (Phase III)
- Collaboration in:
  - 1. Designing of Psoriatic Arthritis Registry of Tehran Rheumatology Research Center
  - 2. Designing of Systemic Lupus Erythematosus Registry of Tehran Rheumatology Research Center
  - 3. Designing of Rheumatoid Arthritis Registry of Tehran Rheumatology Research Center
  - 4. Patient registration for Scleroderma Registry of Tehran Rheumatology Research Center.